Based on these findings, we suggest that the methylation level of ACTB in blood DNA might be a preclinical marker in stroke and reflect a response to stroke in the years preceding clinical diagnosis, which is also supported by previous studies using pre-diagnostic blood samples (Xu et al., 2013, 2020). This evidence concerns the gene ACTB and Stroke.